#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
MADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli Lilly and Bayer. ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.